Yang Hongmei, Hao Yubing, Niu Meili, Zheng Jie, Jia Xinhua, Zhang Shaokai, Wang Libing, Zhang Xun, Pan Qinjing, Feng Xiangxian, Qiao Youlin, Li Zhifang
Department of Public Health and Prevention, Changzhi Medical College, Changzhi, China.
School of Public Health, Shanxi Medical University, Taiyuan, China.
Front Oncol. 2024 Oct 8;14:1416116. doi: 10.3389/fonc.2024.1416116. eCollection 2024.
The research focused on a comparative analysis of triage strategies for women with Atypical Squamous Cells of Undetermined Significance (ASC-US) before and after receiving the HPV vaccine, aiming to optimize cervical cancer prevention strategies, especially in resource-limited healthcare settings.
Between September 2018 and December 2023, 7,511 women aged 21 years or older who underwent liquid-based cytology for cervical cancer screening were recruited. Women diagnosed with ASC-US were included in the study. All participants underwent HPV testing and liquid-based cytology examination, and those with abnormal results were referred for colposcopy. Women with abnormal colposcopy findings underwent further histopathological examination. The gold standard for diagnosis was pathological, with cervical intraepithelial neoplasia grade 2 or higher (CIN2+) on histology as the endpoints. In the final analysis, 933 women with ASC-US were enrolled as the unvaccinated group, with 179 of them testing positive for HPV 16/18. Assuming that all women would receive the bivalent vaccine targeting HPV 16/18 in the post-vaccine era, and given that the vaccine protection rate is 100% against HPV 16/18, then 754 women excluding those of HPV 16/18 positive would comprise the vaccinated group.
In the unvaccinated group, the overall HPV positivity rate was 59.27% among ASC-US women, with a 100% HPV prevalence rate among those with CIN2+ lesions. The combination genotyping model of HPV16/18 showed the highest specificity (81.77%) and the lowest referral rate (32.37%). In the vaccinated group, the HPV positivity rate was 49.61% among ASC-US women, with a 100% HPV prevalence rate among those with CIN2+ lesions. The specificity of HPV33/58 was the highest (86.99%), and the colposcopy referral rate was lowest (27.54%), with statistical significance. Sensitivity, positive predictive value, and negative predictive value were not statistically significant.
HPV16/18 demonstrated a more efficacious triaging effect in the unvaccinated group. HPV33/58 will potentially replace HPV16/18 as the priority screening genotyping among vaccinated populations.
本研究聚焦于对未接种人乳头瘤病毒(HPV)疫苗和接种疫苗后意义未明的非典型鳞状细胞(ASC-US)女性的分诊策略进行比较分析,旨在优化宫颈癌预防策略,尤其是在资源有限的医疗环境中。
2018年9月至2023年12月期间,招募了7511名年龄在21岁及以上接受宫颈癌筛查液基细胞学检查的女性。被诊断为ASC-US的女性被纳入研究。所有参与者均接受HPV检测和液基细胞学检查,结果异常者被转诊进行阴道镜检查。阴道镜检查结果异常的女性接受进一步的组织病理学检查。诊断的金标准是病理学检查,以组织学上宫颈上皮内瘤变2级或更高(CIN2+)为终点。最终分析中,933名ASC-US女性被纳入未接种疫苗组,其中179人HPV 16/18检测呈阳性。假设在疫苗接种后时代所有女性都接种针对HPV 16/18的二价疫苗,且该疫苗对HPV 16/18的保护率为100%,那么排除HPV 16/18阳性者后的754名女性将构成接种疫苗组。
在未接种疫苗组中,ASC-US女性的总体HPV阳性率为59.27%,CIN2+病变者的HPV患病率为100%。HPV16/18联合基因分型模型显示特异性最高(81.77%),转诊率最低(32.37%)。在接种疫苗组中,ASC-US女性的HPV阳性率为49.61%,CIN2+病变者的HPV患病率为100%。HPV33/58的特异性最高(86.99%),阴道镜转诊率最低(27.54%),具有统计学意义。敏感性、阳性预测值和阴性预测值无统计学意义。
HPV16/18在未接种疫苗组中表现出更有效的分诊效果。HPV33/58可能会取代HPV16/18,成为接种疫苗人群中的优先筛查基因分型。